Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

December 5, 2016December 5, 2016

Report Provides Information on 33 New Humira Biosimilar Therapy Candidates for RA

News

PNS Pharma recently released a report titled “Humira Biosimilars Clinical Trial Insight” that includes clinical data on 33 potential new drugs that have a similar action to Humira (adalimumab), an ... Read more

November 18, 2016November 19, 2016

Fewer RA Patients Who Took Remicade Quit Treatment Than Those Who Used Biosimilar CT-P13

News

Treatment of rheumatoid arthritis (RA) with Remicade (infliximab) is associated with lower rates of discontinuation among patients, compared to treatment with CT-P13 (a biosimilar of infliximab), according to results presented by ... Read more

November 17, 2016November 19, 2016

Certain Rheumatoid Arthritis Patients Improved Faster with Baricitinib than Humira, Studies Show

News

Treatment with the investigative drug baricitinib is more effective than Humira (adalimumab), an FDA-approved therapy, in improving joint pain, stiffness and tiredness in patients with rheumatoid arthritis (RA) who have an ... Read more

November 15, 2016November 19, 2016

Pfizer Presents New Positive Results on Xeljanz for Rheumatoid Arthritis

News

Pfizer recently presented encouraging results on the effectiveness and safety of the company’s product Xeljanz (tofacitinib citrate) for the treatment of rheumatoid arthritis (RA). The data was presented at the ACR/ARHP Annual ... Read more

October 7, 2016October 7, 2016

Baricitinib Shows Promise as Potential New Treatment for Rheumatoid Arthritis, Study Shows

News

Treatment with baricitinib improves joint damage in patients with rheumatoid arthritis (RA) who have an inadequate response or intolerance to conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), according to the results of ... Read more

September 23, 2016September 23, 2016

EU Commission Approves Orencia for RA Patients in Combination with Methotrexate

News

The European Commission has approved the use of Orencia (abatacept) by intravenous infusion and injection in combination with methotrexate (MTX) to treat highly active and progressive rheumatoid arthritis (RA) in ... Read more